Skip to content
Assyro AI
Purple Book reference family · 351(a) biologic

Alpha-1-Proteinase Inhibitor (Human) (Aralast, Aralast Np)

Alpha-1-Proteinase Inhibitor (Human) is an FDA-licensed reference biologic from Takeda Pharmaceuticals U.S.A., Inc..

351(a) biologicBLA 125039 Takeda Pharmaceuticals U.S.A., Inc.
Biosimilars
0
Interchangeables
0
Listed patents
0
Reference approved
2002

Reference product

Originator biologic
351(a)BLA 125039

Aralast, Aralast Np Alpha-1-Proteinase Inhibitor (Human)

Takeda Pharmaceuticals U.S.A., Inc.

View full reference-product record
Approved
Marketing
Rx
Center
CBER
Patents
None listed

Molecular structure

RCSB Protein Data Bank

Experimental 3D structure for Alpha-1-Proteinase Inhibitor (Human) from the RCSB Protein Data Bank (PDB 3NE4).

3D molecular structure of Alpha-1-Proteinase Inhibitor (Human) (PDB entry 3NE4)

Interactive biological assembly from PDB entry 3NE4. Drag to rotate, scroll to zoom, and inspect the full atomic structure right here, with no need to leave the page.

Exclusivity & patent cliffs

Protection horizon
  1. Reference approval

    Approval date of the reference Alpha-1-Proteinase Inhibitor (Human) product.

    24 yr 1 mo ago

Alpha-1-Proteinase Inhibitor (Human): frequently asked questions

Reference exclusivity, biosimilars, interchangeability, and patents for this molecule, from the FDA Purple Book.

Built from official FDA Purple Book records (monthly downloads, the Advanced Search interface, and the published Patent List), with reference-product, license-type, and exclusivity context for Alpha-1-Proteinase Inhibitor (Human).

Related FDA reference tools

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.